vabametkib

Vabametkib is a small molecule inhibitor targeting the c-Met (hepatocyte growth factor receptor) tyrosine kinase. It was developed by Abion for the treatment of advanced solid tumors, with a primary focus on non-small cell lung cancer (NSCLC) characterized by MET dysregulation—including MET amplification and MET exon 14 skipping mutations. The drug acts as a selective c-Met inhibitor, blocking signaling pathways involved in tumor growth and survival. Vabametkib has demonstrated promising antitumor activity and an improved safety profile compared to other c-Met inhibitors in early-phase clinical trials. It is currently being evaluated both as monotherapy and in combination with lazertinib (an EGFR inhibitor) for patients who have developed resistance to EGFR-targeted therapies[1][3][4][7].

Other names

vabametkib